Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
August 07, 2018 16:07 ET
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...
Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 17, 2018 18:15 ET
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
May 10, 2018 07:04 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Q Therapeutics Announces Joint Venture With REPROCELL
April 23, 2018 05:00 ET
|
Q Therapeutics, Inc.
PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATIONSALT LAKE CITY and YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) --...
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
February 20, 2018 07:00 ET
|
Wave Life Sciences
Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support Takeda to receive option to co-develop...
Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS
January 24, 2018 16:06 ET
|
ORPHAZYME A/S
Investor newsOrphazyme A/SNo. 01/2018 ...
Q Therapeutics Announces Research Collaboration With REPROCELL
December 13, 2017 07:00 ET
|
Q Therapeutics, Inc.
SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury,...
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
December 11, 2017 07:00 ET
|
Wave Life Sciences
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
August 08, 2017 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
July 27, 2017 07:30 ET
|
Cytokinetics, Inc
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of FORTITUDE-ALS, Functional Outcomes in a Randomized Trial of...